235 related articles for article (PubMed ID: 31576256)
1. Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Maqsood MH; Rubab K; Maqsood MZ
Cureus; 2019 Jul; 11(7):e5263. PubMed ID: 31576256
[TBL] [Abstract][Full Text] [Related]
2. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
3. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.
Hanlon A; Metjian A
Ther Adv Hematol; 2020; 11():2040620720902904. PubMed ID: 32095224
[TBL] [Abstract][Full Text] [Related]
4. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
5. Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.
Mellaza C; Henry N; Fayolle PM; Mortaza S; Subra JF; Veyradier A; Coppo P; Augusto JF
Front Med (Lausanne); 2020; 7():549931. PubMed ID: 33195299
[TBL] [Abstract][Full Text] [Related]
6. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP.
Lee HT; Park UB; Jeong TJ; Gu N; Lee SH; Kim Y; Heo YS
Biochem Biophys Res Commun; 2021 Aug; 567():49-55. PubMed ID: 34144500
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.
Sargentini-Maier ML; De Decker P; Tersteeg C; Canvin J; Callewaert F; De Winter H
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):537-545. PubMed ID: 30977686
[No Abstract] [Full Text] [Related]
8. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
9. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
Kubo M; Matsumoto M
Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
[TBL] [Abstract][Full Text] [Related]
11. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
Chung C
Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
14. Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma.
Irani MS; Sanchez F; Friedman K
Transfusion; 2020 Aug; 60(8):1666-1668. PubMed ID: 32358818
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic thrombocytopenic purpura in caplacizumab era - An individualized approach.
Sarode R
Transfus Apher Sci; 2023 Apr; 62(2):103682. PubMed ID: 36890095
[TBL] [Abstract][Full Text] [Related]
16. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
17. Thrombotic Thrombocytopenic Purpura Masquerading as Acute Ischemic Stroke.
Filatov A; Kassar E; Cole O
Cureus; 2020 Apr; 12(4):e7661. PubMed ID: 32411562
[TBL] [Abstract][Full Text] [Related]
18. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
Bergstrand M; Hansson E; Delaey B; Callewaert F; De Passos Sousa R; Sargentini-Maier ML
J Clin Pharmacol; 2022 Mar; 62(3):409-421. PubMed ID: 34699078
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Tsai HM
Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
